Compare ServiceNow Inc (NOW) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ServiceNow Inc vs Organon & Co. Common Stock — how do they compare? ServiceNow Inc trades at $139.85 (market cap $143.30B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: ServiceNow Inc is far larger — about 39.6× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while ServiceNow Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ServiceNow Inc for 54 Days and Organon & Co. Common Stock for 0 Days on average.
| NOW | OGN | |
|---|---|---|
Market Cap | $143.30B | $3.62B |
Volume | 13,207,010 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $189.26 | $13.81 |
52-Week Low | $83.00 | $5.70 |
Typical Hold Time | 54 Days | 0 Days |
Enterprise Value | $147.09B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ServiceNow (NOW) trades at $138.61, down 1.22% on the day, amid a bullish technical setup with strong analyst support. The stock shows robust fundamentals with revenue growth from $7.2B in 2022 to $13.3B in 2025, a high gross margin of 74.77%, and consistent earnings beats. Recent news highlights AI-driven momentum, with AI annual contract value surpassing $1B in Q2 2026, fueling positive sentiment despite premium valuations.
The outlook remains positive given AI adoption and earnings strength, but risks include stiff competition and high P/E of 86.63. With 87% of analysts rating it Buy and a consensus target of $150.74, the stock offers upside, though investors should weigh valuation concerns against growth prospects.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
